Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1979 Feb;23(2):509–521. doi: 10.1128/iai.23.2.509-521.1979

Passive immunization against Pseudomonas with a ribosomal vaccine-induced immune serum and immunoglobulin fractions.

M M Lieberman, D C McKissock, G L Wright
PMCID: PMC414194  PMID: 106013

Abstract

Passive protection of mice against Pseudomonas aeruginosa using specific antisera and immunoglobulin fractions induced by immunizing rabbits with a ribosomal vaccine is reported. The results demonstrated that protection by the ribosomal vaccine against challenge with live organisms can be serum mediated. Previous work has shown that the vaccine can be separated into two components on the basis of molecular weight and that both higher (peak A)- and lower (peak B)-molecular-weight fractions were capable of inducing active immunity in mice. The present report indicates that both fractions are also capable of eliciting the production of mouse-protective antibody in rabbits. Agar gel diffusion with antisera to peaks A and B or unfractionated vaccine indicated a common antigenic component among them in addition to an extra antigen in unfractionated vaccine not present in peak B. Passive hemagglutination with antisera to peaks A and B demonstrated high-titer agglutinating antibody only with antiserum to peak A when a method of erythrocyte sensitization for lipopolysaccharide antigens was used. Also, passive hemagglutination was greatly inhibited by small amounts of lipopolysaccharide prepared from the same organism from which the vaccine was made. Both antisera to peaks A and B fixed complement with either A or B antigens. Antisera to peaks A and B, when reacted with peak B antigen, had about the same complement fixation titer (as determined by a quantitative complement fixation test). However, when peak A antigen was used, antiserum to peak A had about twice the complement fixation titer that antiserum to peak B had. These results are consistent with previous observations which suggest that the ribosomal vaccine contains lipopolysaccharide in addition to an unidentified immunogenic principle associated with ribosomes. Furthermore, this immunogen was present in both peaks A and B, but detectable amounts of lipopolysaccharide were present only in peak A. The relative importance of the immunoglobulin G (IgG) and IgM classes of antibodies was also compared. The results indicated that both IgG and IgM isolated from immune rabbit serum are protective in mice. Only IgG precipitated with the vaccine in agar gel diffusion, but both IgG and IgM were active in passive hemagglutination and in complement fixation. The passive hemagglutination titer of the IgM was higher than that of the IgG, but the complement fixation titer of the IgG was higher than that of the IgM. The mouse-protective capability of the IgG and IgM was about the same.

Full text

PDF
509

Images in this article

514Image
on p.514
515Image
on p.515
516Image
on p.516

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alms T. H., Bass J. A. Immunization against Pseudomonas aeruginosa. I. Induction of protection by an alcohol-precipitated fraction from the slime layer. J Infect Dis. 1967 Jun;117(3):249–256. doi: 10.1093/infdis/117.3.249. [DOI] [PubMed] [Google Scholar]
  2. Andron LA I. I., Eigelsbach H. T. Biochemical and immunological properties of ribonucleic acid-rich extracts from Francisella tularensis. Infect Immun. 1975 Jul;12(1):137–142. doi: 10.1128/iai.12.1.137-142.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Baba T. Immunogenic activity of a ribosomal fraction obtained from Pasteurella multocida. Infect Immun. 1977 Jan;15(1):1–6. doi: 10.1128/iai.15.1.1-6.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bass J. A., McCoy J. C. Passive immunization against experimental pseudomonas infection: correlation of protection to verder and evans "o" serotypes. Infect Immun. 1971 Jan;3(1):51–58. doi: 10.1128/iai.3.1.51-58.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bjornson A. B., Michael J. G. Biological Activities of Rabbit Immunoglobulin M and Immunoglobulin G Antibodies to Pseudomonas aeruginosa. Infect Immun. 1970 Oct;2(4):453–461. doi: 10.1128/iai.2.4.453-461.1970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Braude A. I., Ziegler E. J., Douglas H., McCutchan J. A. Antibody to cell wall glycolipid of Gram-negative bacteria: induction of immunity to bacteremia and endotoxemia. J Infect Dis. 1977 Aug;136 (Suppl):S167–S173. doi: 10.1093/infdis/136.supplement.s167. [DOI] [PubMed] [Google Scholar]
  7. Cofré G., Calderón I., Mora G. C. Immunogenic capacity of ribosomes of Salmonella typhi interfered with a flagellin-like material contaminant. Infect Immun. 1978 Apr;20(1):161–166. doi: 10.1128/iai.20.1.161-166.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Crowder J. G., Fisher M. W., White A. Type-specific immunity in pseudomonas diseases. J Lab Clin Med. 1972 Jan;79(1):47–54. [PubMed] [Google Scholar]
  9. DEUTSCH H. F., MORTON J. I. Dissociation of human serum macroglobulins. Science. 1957 Mar 29;125(3248):600–601. doi: 10.1126/science.125.3248.600. [DOI] [PubMed] [Google Scholar]
  10. DUBOIS M., GILLES K., HAMILTON J. K., REBERS P. A., SMITH F. A colorimetric method for the determination of sugars. Nature. 1951 Jul 28;168(4265):167–167. doi: 10.1038/168167a0. [DOI] [PubMed] [Google Scholar]
  11. Eisenstein T. K. Evidence for O antigens as the antigenic determinants in "ribosomal" vaccines prepared from Salmonella. Infect Immun. 1975 Aug;12(2):364–377. doi: 10.1128/iai.12.2.364-377.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Fisher M. W. A polyvalent human gamma-globulin immune to Pseudomonas aeruginosa: passive protection of mice against lethal infection. J Infect Dis. 1977 Aug;136 (Suppl):S181–S185. doi: 10.1093/infdis/136.supplement.s181. [DOI] [PubMed] [Google Scholar]
  13. Hirao Y., Homma J. Y. Antigenic relationship between the common antigen (OEP) of Pseudomonas aeruginosa and Vibrio cholerae. Infect Immun. 1978 Feb;19(2):373–377. doi: 10.1128/iai.19.2.373-377.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hoops P., Prather N. E., Berry J., Ravel J. M. Evidence for an extrinsic immunogen in effective ribosomal vaccines from Salmonella typhimurium. Infect Immun. 1976 Apr;13(4):1184–1192. doi: 10.1128/iai.13.4.1184-1192.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Houchens D. P., Wright G. L., Jr Immunity to Salmonella typhimurium infection: characterization of antigens in active protection by polyacrylamide gel electrophoresis. Infect Immun. 1973 Mar;7(3):507–511. doi: 10.1128/iai.7.3.507-511.1973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Johnson W. Ribosomal vaccines. I. Immunogenicity of ribosomal fractions isolated from Salmonella typhimurium and Yersinia pestis. Infect Immun. 1972 Jun;5(6):947–952. doi: 10.1128/iai.5.6.947-952.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Johnson W. Ribosomal vaccines. II. Specificity of the immune response to ribosomal ribonucleic acid and protein isolated from Salmonella typhimurium. Infect Immun. 1973 Sep;8(3):395–400. doi: 10.1128/iai.8.3.395-400.1973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Jones R. J., Hall M., Ricketts C. R. Passive protective properties of serum fractions from mice inoculated with an anti-pseudomonas vaccine. Immunology. 1972 Dec;23(6):889–895. [PMC free article] [PubMed] [Google Scholar]
  19. Lieberman M. M. Direct evidence for the presence of lipopolysaccharide components in Pseudomonas ribosomal vaccine. Infect Immun. 1977 Aug;17(2):471–473. doi: 10.1128/iai.17.2.471-473.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Lieberman M. M. Pseudomonas ribosomal vaccines: preparation, properties, and immunogenicity. Infect Immun. 1978 Jul;21(1):76–86. doi: 10.1128/iai.21.1.76-86.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Liu P. V., Hsieh H. Exotoxins of Pseudomonas aeruginosa. 3. Characteristics of antitoxin A. J Infect Dis. 1973 Oct;128(4):520–526. doi: 10.1093/infdis/128.4.520. [DOI] [PubMed] [Google Scholar]
  22. Lynn M., Tewari R. P., Solotorovsky M. Immunoprotective activity of ribosomes from Haemophilus influenzae. Infect Immun. 1977 Feb;15(2):453–460. doi: 10.1128/iai.15.2.453-460.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Marucci A. A., Fuller T. C. Quantitative micro-complement fixation test. Appl Microbiol. 1971 Feb;21(2):260–264. doi: 10.1128/am.21.2.260-264.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. McCabe W. R., Bruins S. C., Craven D. E., Johns M. Cross-reactive antigens: their potential for immunization-induced immunity to Gram-negative bacteria. J Infect Dis. 1977 Aug;136 (Suppl):S161–S166. doi: 10.1093/infdis/136.supplement.s161. [DOI] [PubMed] [Google Scholar]
  25. Michel F. B., Dussourd D'Hinterland L., Bousquet J., Pinel A. M., Normier G. Immuno-stimulation by a ribosomal vaccine associated with a bacterial cell wall adjuvant in humans. Infect Immun. 1978 Jun;20(3):760–769. doi: 10.1128/iai.20.3.760-769.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Pavlovskis O. R., Iglewski B. H., Pollack M. Mechanism of action of Pseudomonas aeruginosa exotoxin A in experimental mouse infections: adenosine diphosphate ribosylation of elongation factor 2. Infect Immun. 1978 Jan;19(1):29–33. doi: 10.1128/iai.19.1.29-33.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Schalla W. O., Johnson W. Immunogenicity of ribosomal vaccines isolated from group A, type 14 Streptococcus pyogenes. Infect Immun. 1975 Jun;11(6):1195–1202. doi: 10.1128/iai.11.6.1195-1202.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Sensakovic J. W., Bartell P. F. Glycolipoprotein from Pseudomonas aeruginosa as a protective antigen against P. aeruginosa infection in mice. Infect Immun. 1977 Nov;18(2):304–309. doi: 10.1128/iai.18.2.304-309.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Smith R. L., Wysocki J. A., Bruun J. N., De Courcy S. J., Jr, Blakemore W. S., Mudd S. Efficacy of ribosomal preparations from Pseudomonas aeruginosa to protect against intravenous Pseudomonas challenge in mice. J Reticuloendothel Soc. 1974 Jan;15(1):22–30. [PubMed] [Google Scholar]
  30. Snell K., Holder I. A., Leppla S. A., Saelinger C. B. Role of exotoxin and protease as possible virulence factors in experimental infections with Pseudomonas aeruginosa. Infect Immun. 1978 Mar;19(3):839–845. doi: 10.1128/iai.19.3.839-845.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Swendsen C. L., Johnson W. Humoral immunity to Streptococcus pneumoniae induced by a pneumococcal ribosomal protein fraction. Infect Immun. 1976 Aug;14(2):345–354. doi: 10.1128/iai.14.2.345-354.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Tewari R. P., Lynn M., Birnbaum A. J., Solotorovsky M. Characterization of the immunoprotective antigen of ribosomal preparations from Haemophilus influenzae. Infect Immun. 1978 Jan;19(1):58–65. doi: 10.1128/iai.19.1.58-65.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Thompson H. C., Eisenstein T. K. Biological properties of an immunogenic pneumococcal subcellular preparation. Infect Immun. 1976 Mar;13(3):750–757. doi: 10.1128/iai.13.3.750-757.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Venneman M. R., Berry L. J. Serum-mediated resistance induced with immunogenic preparations of Salmonella typhimurium. Infect Immun. 1971 Oct;4(4):374–380. doi: 10.1128/iai.4.4.374-380.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Venneman M. R. Purification of immunogenically active ribonucleic acid preparations of Salmonella typhimurium: molecular-sieve and anion-exchange chromatography. Infect Immun. 1972 Mar;5(3):269–282. doi: 10.1128/iai.5.3.269-282.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Wesley J., Fisher A., Fisher M. W. Immunization against Pseudomonas in infection after thermal injury. J Infect Dis. 1974 Nov;130 (Suppl)(0):S152–S158. doi: 10.1093/infdis/130.supplement.s152. [DOI] [PubMed] [Google Scholar]
  37. Winston S., Berry L. J. Immunity induced by ribosomal extracts from Staphylococcus aureus. J Reticuloendothel Soc. 1970 Jul;8(1):66–73. [PubMed] [Google Scholar]
  38. Youmans A. S., Youmans G. P. Immunogenic mycobacterial ribosomal and ribonucleic Acid preparations: chemical and physical characteristics. Infect Immun. 1970 Nov;2(5):659–668. doi: 10.1128/iai.2.5.659-668.1970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Youmans A. S., Youmans G. P. Preparation of highly immunogenic ribosomal fractions of Mycobacterium tuberculosis by use of sodium dodecyl sulfate. J Bacteriol. 1966 Jun;91(6):2139–2145. doi: 10.1128/jb.91.6.2139-2145.1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Young L. S., Armstrong D. Human immunity to Pseudomonas aeruginosa. I. In-vitro interaction of bacteria, polymorphonuclear leukocytes, and serum factors. J Infect Dis. 1972 Sep;126(3):257–276. doi: 10.1093/infdis/126.3.257. [DOI] [PubMed] [Google Scholar]
  41. Young L. S., Stevens P. Cross-protective immunity to Gram-negative bacilli: studies with core glycolipid of Salmonella minnesota and antigens of Streptococcus pneumoniae. J Infect Dis. 1977 Aug;136 (Suppl):S174–S180. doi: 10.1093/infdis/136.supplement.s174. [DOI] [PubMed] [Google Scholar]
  42. Zinner S. H., McCabe W. R. Effects of IgM and IgG antibody in patients with bacteremia due to gram-negative bacilli. J Infect Dis. 1976 Jan;133(1):37–45. doi: 10.1093/infdis/133.1.37. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES